Document Details

Document Type : Article In Journal 
Document Title :
Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeutics
Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeutics
 
Document Language : English 
Abstract : The S100A8 and epidermal growth factor receptor (EGFR) proteins are proto-oncogenes that are strongly expressed in a number of cancer types. EGFR promotes cellular proliferation, differentiation, migration and survival by activating molecular pathways. Involvement of proinflammatory S100A8 in tumor cell differentiation and progression is largely unclear and not studied in kidney cancer (KC). S100A8 and EGFR are potential therapeutic biomarkers and anticancer drug targets for KC. In this study, we explored molecular mechanisms of interaction profiles of both molecules with potential anticancer drugs. We undertook transcriptional profiling in Saudi KCs using Affymetrix HuGene 1.0 ST arrays. We identified 1478 significantly expressed genes, including S100A8 and EGFR overexpression, using cut-off p value <0.05 and fold change ≥2. Additionally, we compared and confirmed our findings with expression data available at NCBI's GEO database. A significant number of genes associated with cancer showed involvement in cell cycle progression, DNA repair, tumor morphology, tissue development, and cell survival. Atherosclerosis signaling, leukocyte extravasation signaling, notch signaling, and IL-12 signaling were the most significantly disrupted signaling pathways. The present study provides an initial transcriptional profiling of Saudi KC patients. Our analysis suggests distinct transcriptomic signatures and pathways underlying molecular mechanisms of KC progression. Molecular docking analysis revealed that the kinase inhibitor "midostaurin" has amongst the selected drug targets, the best ligand properties to S100A8 and EGFR, with the implication that its binding inhibits downstream signaling in KC. This is the first structure-based docking study for the selected protein targets and anticancer drug, and the results indicate S100A8 and EGFR as attractive anticancer targets and midostaurin with effective drug properties for therapeutic intervention in KC. 
ISSN : 1932-6203 
Journal Name : PloS one 
Volume : 10 
Issue Number : 3 
Publishing Year : 1436 AH
2015 AD
 
Article Type : Article 
Added Date : Monday, April 25, 2016 

Researchers

Researcher Name (Arabic)Researcher Name (English)Researcher TypeDr GradeEmail
Zeenat MirzaMirza, Zeenat Investigator  
Hans-Juergen SchultenSchulten, Hans-Juergen Researcher  
Hasan Ma FarsiFarsi, Hasan MaResearcher  
Jaudah A. Al-MaghrabiAl-Maghrabi, Jaudah A.Researcher  
Mamdooh A. GariGari, Mamdooh A.Researcher  
Adeel Ga ChaudharyChaudhary, Adeel GaResearcher  
Adel M. AbuzenadahAbuzenadah, Adel M.Researcher  
Mohammed H. Al- QahtaniAl- Qahtani, Mohammed H.Researcher  
Sajjad KarimKarim, Sajjad Researcher  

Files

File NameTypeDescription
 38677.pdf pdf 

Back To Researches Page